Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine)… Dec 15, 2021
Cybin Strengthens IP Portfolio By Filing Of 16th Patent Application: Psychedelic Investors React Aug 20, 2021
Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs Aug 19, 2021
Cybin Completes Its 51st Pre-Clinical Study of Psychedelic Compounds for Mental Health Treatment Jun 30, 2021
Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug… Apr 13, 2021
